Jpmorgan Chase & CO Gamida Cell Ltd. Transaction History

Jpmorgan Chase & CO

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 11, 2023	SELL	$0.73 - $2.37 $306,542 - $995,212	-419,921 Reduced 99.56%	1,838 $3,000
Q4 2022 Feb 13, 2023	SELL	$1.15 - $2.1 $2,725 - $4,977	-2,370 Reduced 0.56%	421,759 $544,000
Q3 2022 Nov 14, 2022	SELL	$1.53 - $3.39 $157,948 - $349,963	-103,234 Reduced 19.58%	424,129 $675,000
Q2 2022 Aug 11, 2022	SELL	$1.73 - $4.29 $352,859 - $875,009	-203,965 Reduced 27.89%	527,363 $933,000
Q1 2022 May 11, 2022	BUY	$2.22 - $4.47 $184,279 - $371,050	83,009 Added 12.8%	731,328 $3.04 Million
Q4 2021 Feb 10, 2022	BUY	$2.2 - $4.46 $110,492 - $223,999	50,224 Added 8.4%	648,319 $1.65 Million
Q3 2021 Nov 12, 2021	BUY	$3.85 - $6.44 $2.3 Million - $3.85 Million	598,095 New	598,095 $2.34 Million

2.2K

Ticker GMDA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 76,319,600
Market Cap $2.29M
Description
Gamida Cell Ltd., a clinical-stage biopharmaceutical company, develops cell therapies to cure blood cancers and serious hematologic diseases. The company's lead product candidate is omidubicel, a cell therapy that has completed Phase III clinical trial in patients with high-risk hematologic malignancies, as well as in Phase I/II clinical trials ...

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

Stay updated on Jpmorgan Chase & CO with notifications on news.